

July 19, 2024

BSE Limited Code: 532321

1<sup>st</sup> Floor, P J Towers, Dalal Street, Mumbai-400001

## National Stock Exchange of India Limited

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated July 19, 2024 titled "Stock Exchange intimation on completion of USFDA inspection at transdermal manufacturing site".

Code: Zyduslife

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, ZYDUS LIFESCIENCES LIMITED

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



## Stock Exchange intimation on completion of USFDA inspection at transdermal manufacturing site

Ahmedabad, India, 19 July, 2024

We wish to inform that the USFDA conducted an inspection at the group's transdermal manufacturing site located at SEZ in Ahmedabad. The inspection was conducted from July 15 to 19, 2024.

The inspection closed with 2 observations. The Company is confident of addressing the issues raised by the USFDA within the stipulated timeline, and is committed to resolving the same at the earliest.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

\*\*\*



For further information please contact: The Corporate Communications Department

## **Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com CIN : L24230GJ1995PLC025878